Contributory role of ART in the development of non-AIDS comorbidities in asymptomatic PLWHA

Karen Ingrid Tasca 1 *, Vânia V. M. Fagundes Vidal 2, Vanessa Martinez Manfio 3, Alexandre Naime Barbosa 2, 3, Lenice do Rosário de Souza 2, 3

1 São Paulo State University – UNESP, Institute of Biosciences of Botucatu, Department of Microbiology and Immunology, Botucatu, São Paulo State, Brazil
2 Specialist Outpatient Service for Infectious Diseases “Domingos Alves Meira” (SAEI-DAM), Botucatu, São Paulo State, Brazil
3 São Paulo State University – UNESP, Botucatu Medical School, Department of Tropical Diseases and Imaging Diagnosis, Botucatu, São Paulo State, Brazil

Abstract

Background: Despite the many benefits that follow antiretroviral therapy (ART) initiation, its chronic use contributes to the early aging of people living with HIV/AIDS (PLWHA). The aim of this cross-sectional study was to trace the prevalence of and investigate possible renal, bone and metabolic changes, as well as cardiovascular risk in 94 asymptomatic PLWHA, relating them to the duration of ART use.

Methods: Four groups were evaluated according to ART use: G1 (n = 21), ART-naïve individuals; G2 (n = 17), <2 years; G3 (n = 40), 2–10 years; and G4 (n = 16) on ART for more than 10 years.

Results: Our results showed a high prevalence of dyslipidemic individuals (64%), especially in those under ART. Lower creatine phosphokinase levels were observed in G1 as compared to the others (p < 0.05). Regarding the Framingham score, 12.1% of PLWHA showed moderate and high risk, and the highest proportion (38.5%) occurred in G4 (p = 0.003). A decrease in glomerular filtration rates occurred in 20% of patients, which was also more significant in G3 and G4 (p = 0.007). High prevalences of osteopenia and osteoporosis (53.2%) were found, especially in G1 and G4; however, G1 showed the lowest means for alkaline phosphatas (AP, p = 0.04 and BAP, p = 0.005) and osteocalcin (p = 0.005), in addition to higher vitamin-D concentrations (p = 0.04).

Conclusions: Our study showed the possible contributory role of ART in these changes, which leads us to reflect on the need for specific conducts and patient care, pointing out the importance of individualized care in an attempt to increase life expectancy.

Keywords: Antiretroviral; Dyslipemia; HIV/AIDS; Non-AIDS comorbidities

Highlights:
• The chronic use of ART compromises metabolic, hepatic, bone and renal function.
• There is a higher risk of cardiovascular event (Framingham score) in patients on ART for more than 10 years.
• Bone changes can be observed in ART-naïve patients, showing the direct role of HIV in such disturbances.

Introduction

Today, with the access to antiretroviral therapy (ART) and good health care, the life expectancy of a person living with HIV/AIDS (PLWHA) is very similar to that of the general population. According to the World Health Organization, expanding access to treatment (“test-and-treat” strategy) is one of the three main goals set for 2020, with the aim of controlling the AIDS epidemic as a threat to public health by 2030 (UNAIDS, 2019).

Despite the unquestionable long-term advantages of ART, early intervention has shown not only clinical benefits and, in this context, new challenges are present. Looking at the cause of PLWHA deaths today, there is a great occurrence (with an earlier onset) of typical diseases of aging such as ischemic heart disease, stroke and other central nervous system disorders, dyslipidemia, liver disease, chronic kidney disease (CKD), diabetes mellitus (DM), bone changes and non-AIDS-related cancers (d’Arminio et al., 2019; Deeks, 2011; Guaraldi et al., 2011; Smith et al., 2014; Suligoi et al., 2018). This phenomenon, known as “premature aging”, is a reflection not only of the adverse effects of therapy, but also of the persistent inflammatory process resulting from constant replication of HIV, even when it is residual, as in asymptomatic individuals (d’Arminio et al., 2019; Deeks, 2011; Guaraldi et al., 2011; Smith et al., 2014; Suligoi et al., 2018).

In PLWHA, the finding of osteopenia and osteoporosis is common, with an estimated prevalence three times as high as that in individuals without the virus (Brown and Qaqish, 2011).
In addition to known risk factors, such as chronic alcohol use and smoking, hormonal disorders, low body weight, vitamin-D deficiency, corticosteroid use and lack of exercise, both HIV infection and ART use, regardless of the antiretroviral regimen, also contribute to the reduction of bone mineral density (BMD), especially the use of tenofovir (Bolland et al., 2006; Bonjoch et al., 2010; Brown et al., 2009).

During effective ART, CKD has also gained prominence due to its much higher prevalence in PLWHA, with rates close to 8%, while in the general population such rates are only seen in people over 60 years old (Lugon, 2009; Menezes et al., 2011). Classically, the main factors associated with increased risk for CKD are age over 60 years, ethnicity (African descendants, Hispanics, Asians and Indians), female gender, low body weight, family history of CKD, diabetes mellitus, metabolic syndrome (including dyslipidemia), recurrent urinary infections, cardiovascular disease, systemic arterial hypertension, smoking and obesity. In PLWHA, other potential factors are longer HIV infection, longer ART use, presence of tenofovir, indinavir and atazanavir in the treatment regimen, low CD4+ T lymphocyte count and presence of opportunistic infections (Detti et al., 2010; Lugon, 2009; Menezes et al., 2011; Mocroft et al., 2007).

Regarding the risk for cardiovascular disease, longer ART use, especially that containing abacavir and protease inhibitors (PI), seems to increase the risk for myocardial infarction (Dorjee et al., 2018; Friis-Moller et al., 2003; Worm et al., 2010). The study Data Collection on Adverse Events of Anti-HIV Drugs showed that the relative increase in risk for myocardial infarction was 26% per year of drug exposure (Friis-Moller et al., 2003). Again, one factor contributing to these high rates is metabolic syndrome as a consequence of antiretroviral use, including dyslipidemia, insulin resistance, overweight and obesity (Wand et al., 2007).

Thus, this study aimed to investigate in PLWHA, both in treatment-naive and in those on ART and with adequate viral suppression (undetectable HIV plasma viral load), the prevalence of non-AIDS comorbidities, especially renal, bone and metabolic changes and cardiovascular risk and the relationship of such alterations with the length of time of ART use.

### Material and methods

#### Study design

This cross-sectional study was conducted from 2014 to 2018 at the Specialized Outpatient Service for Infectious Diseases “Domingos Alves Meira” (SAEI-DAM) – Botucatu Medical School Complex (FMB)-UNESP, in São Paulo state, Brazil. The convenience sample totaled 94 HIV-infected adults included in the study, divided into four groups according to the duration of ART use: G1→ ART-naïve (n = 21); G2→ on ART for less than two years (n = 17); G3→ on ART for two to 10 years (n = 40); G4→ on ART for more than 10 years (n = 16).

#### Inclusion and exclusion criteria

The patient inclusion criteria were age between 18 and 50 years, signing an informed consent form and belonging to a study group, as mentioned above. As to the individuals in the ART groups, only those who had an undetectable viral load at the time of inclusion were included.

Those with a cancer history (current or previous), anorexia, morbid obesity, diabetes mellitus, cardiovascular, genetic or autoimmune diseases, organ transplants, pregnancy, coinfections such as tuberculosis, chronic viral hepatitis, cerebral or disseminated toxoplasmosis, and use of illicit drugs or alcohol were excluded.

### Sociodemographic and clinical data

The complementary data (sociodemographic factors, metabolic and biochemical tests and HIV viral load (VL) quantifications) were collected from electronic medical records relative to the date of blood collection for this study.

#### Laboratory tests

12 ml of blood was collected and centrifuged at 1,500 rpm for 10 min. Some plasma aliquots per individual were stored at −80 °C until all the assays were conducted at the Tropical Diseases Laboratory of the Botucatu Medical School (FMB/UNESP), Flow Cytometry and Molecular Biology Laboratories at the Botucatu Blood Center and Clinical Analyses Laboratory, both belonging to the Botucatu University Hospital (FMB/HC), SP, Brazil.

#### Analysis of bone changes

- Osteocalcin (OC) and bone alkaline phosphatase (BAP): MicroVue Osteocalcin EIA (enzyme immunoassay) kit and MicroVue BAP ELISA – QUIDEL® (USA, CA, San Diego).
- Collagen type-I carboxyterminal telopeptide (s-CTX): Cross Linked C-telopeptide of type-I collagen, ELISA kit – ELABSCIENCE (USA).
- 25-OH vitamin D: 3L52 ARCHITECT 25-OH Vitamin-D kit, an immunoassay of microparticles by chemiluminescence (CMIA).
- Dual emission x-ray absorptiometry (DXA): Dual-Energy X-Ray Absorptiometry, in a Hologic Discovery-A device, is the test that evaluates bone mineral density and risk for fracture. It is considered gold standard for osteoporosis diagnoses. The results were interpreted under two aspects, that is, by comparison with data from individuals at the same age group and with similar bone mineral density. They were also classified according to WHO consensus (Kanis et al., 2008).
- Fracture Risk Assessment Tool (FRAX): It is an epidemiological index developed to combine the various risk factors for osteoporotic fracture, which enables the calculation of the absolute risk for fracture in 10 years, thus identifying high-risk patients (Kanis, 2007; Kanis et al., 2008).

#### Renal function analysis

- Calculation of the glomerular filtration rate (GFR): GFR was calculated concomitantly by the three most commonly used serum estimation formulas as recommended by nephrology societies: Cockcroft-Gault, MDRD and CKD-EPI. In order to simplify calculations and avoid errors, we used an electronic application made available by the National Kidney Foundation (2011), which makes it possible to enter data and obtain results automatically. For CKD-EPI score categorization, the following stages were considered: 1: ≥90; 2: 60–89; 3: 30–59; 4: 15–29; 5: <15 ml/min/1.73 m² or dialysis.

#### Cardiovascular disease risk assessment

- Framingham Score: the scores 1, 2 and 3 were used to assess the risk for cardiovascular events in 10 years. The risk can be considered low (<10), moderate (10–20) or high (>20) respectively (Wilson et al., 1998).
Assessment of inflammatory status and metabolic disorders

- Creatinophosphokinase (CPK), lactic dehydrogenase (LDH) and C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), creatinine, urea and parathormone (PTH), total cholesterol and fractions (high-density lipoprotein, HDL and low-density lipoprotein, LDL), triglycerides (TG), glucose, body mass index (BMI): results were collected from electronic medical records. Dyslipidemia was considered when the subject had isolated hypercholesterolemia (LDL >160 mg/dl), isolated hypertriglyceridemia (TG >150 mg/dl) or low HDL (<40 or <50 mg/dl, if male or female, respectively) (Faludi et al., 2017).

Analysis of results

Statistical analysis was performed respecting the assumptions determined by the results, characteristics and behavior of the study variables. Thus, considering the continuous variables and using the Shapiro–Wilk test to analyze normality, the following tests were applied: for non-parametric variables, Gamma Distribution or Kruskal–Wallis; for parametric variables, Multiple Comparisons (ANOVA) followed by Tukey’s Test. Considering the categorical variables, association tables and Chi-square were analyzed. Significant differences were considered when p values were less than or equal to 0.05. All these procedures were performed with help from professionals at the institution’s Research Support Office using SAS for Windows, version 9.2.

Results and discussion

Sociodemographic and clinical data

The sociodemographic, clinical and therapeutic characterization of the studied PLWHA is shown in Supplemental Digital Content. Of the 94 patients included, most were male (n = 50, 53.2%), white (n = 75, 79.8%) and had a mean age of 37 ± 9 years. The groups were homogeneous as regards gender, skin color, smoking habits, social drinking, use of other medications in addition to antiretrovirals and physical activity (p > 0.05). Considering age, gender and skin color, our data were in accordance with data reported in Brazil in 2019, where most cases of HIV infection were in the range of 20 to 34 years, 69% were male and 40.9% were white people (Brasil, MS, 2019).

However, the groups were heterogeneous as to the mean age of their members, with G4 being composed of older people, which was expected considering that these patients had been on ART for more than 10 years. Other differences found between the groups were related to the time since diagnosis and the number of changes in ART regimens, which were both also greater in G4.

At the time of diagnosis, G1 showed a lower CD4+ T lymphocyte count than the other groups and VL above the detection limit for the majority (95.2%) of the individuals. The conditions shown by such individuals portrayed a recent diagnosis of the infection because blood collection was performed in the pre-treatment period, considering that the beginning of ART is immediate after diagnosis confirmation in Brazil, according to current recommendations by the Ministry of Health (Brasil, MS, 2018). For most individuals, VL is expected to become undetectable and T CD4+ counts will increase considerably after six months of treatment, as shown by a study by our group, published in 2013 (Fukumoto et al., 2013).

Metabolic variables

HIV infection alone already changes the metabolic profile of patients, and it is associated with a reduction in lipid levels, weight loss and protein depletion. But these levels rise in the long term, with the initiation and maintenance of ART (Mgogewe et al., 2012; Pinto Neto et al., 2013; Young et al., 2005). Even after therapy initiation, it is observed that 33.0% to 82.0% of patients develop hypercholesterolemia and 43.0% to 66.0% hypertriglyceridemia (Brasil, MS, 2008). These are changes that mainly contribute to the development of cardiovascular diseases (Balla et al., 2017). In our study, considering all patients, these prevalences were lower, at 5.3% and 33.0% respectively, being more frequent in the groups under ART, than in the naive group. However, when also considering low HDL values, we had more than 60.0% of dyslipidemics. The means for glucose, total cholesterol, HDL, LDL and TG are shown in Fig. 1B. We found that total cholesterol levels were higher in G4 than in G1. These findings have been corroborated by other studies (Pinto Neto et al., 2013; Souza et al., 2013; Vos et al., 2018), indicating that ART actually has a role in changing the metabolic profile of patients, and this action is enhanced with years of therapy (Pinto Neto et al., 2013; Vos et al., 2018). It was even possible to observe here a positive correlation between total cholesterol and ART duration (p = 0.001). However, it is noteworthy that this association may have an influence on age and time since HIV diagnosis, variables that were also positively correlated with total cholesterol levels (p = 0.002 and p = 0.007, respectively).

Souza et al. (2013) showed, in a review study, that metabolic changes vary according to the therapeutic regimen. Most individuals on therapy for the longest time had been using regimens containing PI and, therefore, this is another fact that is related to a greater metabolic disorder (Brasil, MS, 2018). Thus in this study, there was an association between PI use and higher means of total cholesterol (p = 0.003), TG (p = 0.029) and HDL (p = 0.018). Instead, Hidalgo et al. (2018) found that, in clinically stable middle-aged adults receiving predominantly initial NRTI-based ART, a high proportion of metabolic comorbidities was found, with dyslipidemia, obesity and type-2 DM being the most frequent, and there was also an association of these disorders with the longest duration of ART and older age. However, in general the HDL mean also increased in G4. When our results were categorized, a high proportion (45.7%) of individuals showed HDL below normality parameters, especially those ART naive. Increase in HDL may occur after the introduction of ART, resulting in a cardioprotective effect; however, the other lipid fractions also increase (Dai et al., 2019), which enhances the risk for metabolic syndrome. In fact, the SMART study found a decrease in HDL levels after NRTI interruption, which was associated with increased cardiovascular risk (Duprez et al., 2009).

Additional parameters were collected (Table 1) for a more complete biochemical analysis. CRP, a protein that in high blood concentration indicates inflammatory or infectious processes, along with IL-6, is related to the progression of HIV/AIDS infection (Neaton et al., 2010). In this study, there was no difference in CRP levels between the groups (Table 1), whose means were within normal limits. However, in a previous study carried out by our group (Tasca et al., 2016), there was an increase in CRP in the first six months after the introduction of ART. Considering these two findings, we suggest that a transient alteration of this marker
may occur in the initial months of ART, with later normalization. This explanation can be corroborated by Bestawros et al. (2015), who found a decrease in CRP levels after one year of ART, despite remaining at relatively higher levels than in the uninfected population.

In this study, there was no correlation between LDH levels and ART duration ($p = 0.075$), with the highest mean found in G1, as compared to G4. This observation may reflect another association found here, between increased LDH and NRTI use ($p = 0.025$), which was most frequently observed in G1. In addition, Ramana et al. (2013) found a reduction in LDH after three to six months of ART use. Additionally, it was possible to observe a positive correlation between LDH with aspartate and alanine aminotransferases (AST, $p < 0.0001$; ALT, $p = 0.02$). Among other common causes of increased LDH are Pneumocystis infection, acute myocardial, lung and kidney infarction, hepatitis, alcoholism, acute pancreatitis, bone fractures and intestinal obstruction. Few studies address this parameter in the evolution of HIV infection or of diseases associated with AIDS or not. Therefore, its use as an inflammatory marker still needs to be better clarified.

In our study, the mean CPK concentrations appeared to increase according to ART duration because G4 had higher results than did the other groups. We observed a positive correlation between CPK and ART duration ($p = 0.029$), TG ($p = 0.023$) and total cholesterol ($p = 0.013$). CPK is an enzyme that acts mainly on muscle tissues, including the heart and brain, and its dosage is necessary to investigate possible damage to these organs. However, elevated CPK levels and myopathies have been associated with the use of raltegravir (Madeddu et al., 2015a). In this study, only three (3.2%) patients were using this specific drug, all belonging to G4, but it was not possible to observe a correlation between its use and CPK means ($p = 0.490$). Therefore, further studies on the long-term effects of this class of drugs should be performed, considering that currently, the use of integrase inhibitors is indicated.

---

**Table 1.** Biochemical examinations of the studied PLWHA

<table>
<thead>
<tr>
<th></th>
<th>G1 (n = 21)</th>
<th>G2 (n = 17)</th>
<th>G3 (n = 40)</th>
<th>G4 (n = 16)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ME (SD)</td>
<td>ME (SD)</td>
<td>ME (SD)</td>
<td>ME (SD)</td>
<td></td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>0.7 (0.4)</td>
<td>0.8 (0.5)</td>
<td>0.8 (0.4)</td>
<td>0.7 (0.3)</td>
<td>NS</td>
</tr>
<tr>
<td>CPK (U/l)</td>
<td>110.9 (53.2)</td>
<td>120.0 (128.9)</td>
<td>130.7 (153.8)</td>
<td>213.5 (276.5)*</td>
<td>0.0273G1</td>
</tr>
<tr>
<td>LDH (U/l)</td>
<td>506.1 (145.1)</td>
<td>472.3 (86.9)</td>
<td>435.5 (78.7)</td>
<td>433.9 (89.2)</td>
<td>0.046G3</td>
</tr>
</tbody>
</table>

PLWHA: People living with HIV/AIDS; G1: PLWA antiretroviral therapy (ART)-naive; G2: PLWA under ART for less than 2 years; G3: PLWA under ART for 2 to 10 years; G4: PLWA on ART for more than 10 years. ME: Mean; SD: Standard Deviation; CRP: C-reactive protein; CPK: Creatinophosphokinase; LDH: Lactic Dehydrogenase; NS: Not Significant. Statistical test used: Multiple Comparison (ANOVA) followed by Tukey–Kramer post hoc tests; * $p = 0.035$ (G1$+$G4); # $p = 0.023$ (G1$+$G4); <0.0001 (G2$+$G4); 0.006 (G3$+$G4).
as a first-line regimen in Brazil (Brasil, MS, 2018) and in other countries.

**Cardiovascular diseases**

Dyslipidemia, insulin resistance and cardiovascular diseases are the most frequent side effects occurring in people using ART (Brasil, MS, 2018; Pinto Neto et al., 2013; Souza et al., 2013; Vos et al., 2018). As previously shown, more than 60.0% of our patients had dyslipidemia, with a greater proportion in the ART groups, which leads us to suggest greater cardiovascular risk in these groups. In addition, the virus itself appears to have a direct action on the circulatory system, including the systemic, pulmonary arterial wall and the myocardium (Faludi et al., 2017; Hajjar et al., 2005). With this regard, in an ART-naive Italian cohort followed for 10 years, the percentage of people in the high-risk group for the Framingham score more than tripled (from 13.0% to 45.0%), which points to the likely effect of aging and HIV infection, as well as this interaction (d’Arminio et al., 2019).

Egger et al. (2001) also used this score to assess cardiovascular risk in ART patients and the main causes of risk were age, gender, smoking and even ART use. In our study, the increase in this score was also clear according to the length of therapy use (Fig. 2). In the general analysis of patients and considering the categorization of risk into low, moderate and high, 12.1% had moderate- and high-risk scores, the highest proportion being found in G4 (G1: 6.2%; G2: 0%; G3: 9.5% and G4: 38.5%). Observational studies have shown high rates of acute myocardial infarction or other coronary diseases in PLWHA versus healthy individuals, with the risk of these events being approximately twice as high in those on ART as compared to treatment naïves (Bergersen et al., 2004; Triant, 2013).

![Fig. 2. Framingham score of the studied PLWHA.](Image)

**Kidney diseases**

In times of effective ART, CKD has also gained prominence as an entity of much higher prevalence in PLWHA, with rates ranging from 4.0% to 9.0%, while in the general population, these rates are only seen in people over 60 years (Crum-Cianflone et al., 2010; Menezes et al., 2011; Mocroft et al., 2007). Following the criteria adopted by the National Kidney Foundation (CKD-EPI – Chronic Kidney Disease Epidemiology Collaboration) (2011), the prevalence of reduced renal function (or stage 3, eGFR < 60 ml/min/1.73 m²) in the population studied here was 3%, with these patients belonging to G3. Similarly, a study on other Brazilian HIV cohort by Bonotto et al. (2016), obtained a prevalence of 3.5% in patients with approximately 10 years of infection and ART use. Mocroft et al. (2007), in a cohort of HIV-positive individuals from 31 countries in Europe, Israel and Argentina found a prevalence of 4.5%. In this study, the overall prevalence of slightly reduced kidney function (stage 2, eGFR 60–89 ml/min/1.73 m²) was 17.0% (n = 16), a rate slightly lower than that found by Cristelli et al. (2018), 25% in adult Spanish individuals on ART. However, in our study, a much higher prevalence was found in patients on ART for many years, and the following frequencies were found, according to the study groups: 9.5% in G1, 11.8% in G2, 12.5% in G3 and 43.7% in G4 (Fig. 3).
In addition, authors reported that the factors associated with the risk for CKD were longer HIV infection, longer ART use, tenofovir use and association with diabetes (Mocroft et al., 2007). In our study, worse renal function was associated with ART use \( p = 0.009 \), longer therapy \( p < 0.0003 \) and long infection \( p = 0.004 \), in addition to higher glucose \( p = 0.044 \) and TG \( p = 0.005 \) levels and older age \( p = 0.001 \).

The means for creatinine, urea and GFR found in this study are shown below, in Table 2. Urea was positively correlated with the time since diagnosis \( p = 0.013 \) and length of ART \( p = 0.027 \).

However, the risk factors associated with mild renal impairment have been poorly studied in HIV-infected patients and, due to the asymptomatic character of this condition, patients are often not recognized as having kidney disease and, therefore, early interventions, such as ART change and comorbidity treatment, are not usual.

### Table 2. Renal and Bone changes presented by the studied PLWHA

<table>
<thead>
<tr>
<th></th>
<th>G1 (n = 21)</th>
<th>G2 (n = 17)</th>
<th>G3 (n = 40)</th>
<th>G4 (n = 16)</th>
<th>( p ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Creatinine</td>
<td>MED (MIN-MAX)</td>
<td>ME ± SD</td>
<td>ME ± SD</td>
<td>ME ± SD</td>
<td>ME ± SD</td>
</tr>
<tr>
<td></td>
<td>0.8 (0.8–0.9)</td>
<td>0.9 (0.7–1.0)</td>
<td>0.9 (0.8–1.0)</td>
<td>0.9 (0.7–1.0)</td>
<td>NS</td>
</tr>
<tr>
<td>GFR – CKD-EPI</td>
<td>ME ± SD</td>
<td>110.7 ± 10.6a</td>
<td>106.2 ± 18.1</td>
<td>95.4 ± 17.5b</td>
<td>91.6 ± 18.9b,c</td>
</tr>
<tr>
<td>Urea</td>
<td>ME ± SD</td>
<td>25.8 ± 6.4</td>
<td>29.6 ± 9.6</td>
<td>29.4 ± 8.5</td>
<td>31.5 ± 8.0c</td>
</tr>
<tr>
<td>Serum Calcium (mg/dl)</td>
<td>ME±SD</td>
<td>9.3 ± 0.8</td>
<td>9.1 ± 0.7</td>
<td>9.6 ± 0.8</td>
<td>9.1 ± 0.7</td>
</tr>
<tr>
<td>Serum Phosphorus (mg/dl)</td>
<td>ME ± SD</td>
<td>3.4 ± 0.5</td>
<td>3.2 ± 0.7</td>
<td>3.4 ± 0.5</td>
<td>3.6 ± 0.6</td>
</tr>
<tr>
<td>Serum Alkaline Phosphatase (U/l)</td>
<td>ME (MIN-MAX)</td>
<td>66.0a (55.0–79.7)</td>
<td>95.0 (90.0–106.0)</td>
<td>92.5 (78.5–109.0)</td>
<td>99.0 (86.2–121.5)</td>
</tr>
<tr>
<td>PTH (pg/dl)</td>
<td>MED (MIN-MAX)</td>
<td>24.5b (15.3–29.9)</td>
<td>41.1 (27.5–55.3)</td>
<td>35.0 (22.1–46.2)</td>
<td>36.8 (29.2–56.1)</td>
</tr>
<tr>
<td>Serum Vitamin D (ng/ml)</td>
<td>ME ± SD</td>
<td>40.9 ± 14.2a</td>
<td>34.2 ± 12.9b, b</td>
<td>30.4 ± 8.7b</td>
<td>30.6 ± 10.2b</td>
</tr>
<tr>
<td>Femur BMD (g/cm²)</td>
<td>MED (MIN-MAX)</td>
<td>0.9 (0.8–0.9)</td>
<td>0.9 (0.8–0.9)</td>
<td>0.8 (0.8–0.9)</td>
<td>0.8 (0.7–1.0)</td>
</tr>
<tr>
<td>Lumbar spine BMD (g/cm²)</td>
<td>ME ± SD</td>
<td>0.9 ± 0.2</td>
<td>1.0 ± 0.1</td>
<td>1.0 ± 0.1</td>
<td>1.0 ± 0.2</td>
</tr>
<tr>
<td>CTX-I (ng/ml)</td>
<td>MED (MIN-MAX)</td>
<td>0.1 (0.0–0.5)</td>
<td>0.1 (0.0–0.3)</td>
<td>0.1 (0.0–0.3)</td>
<td>0.0 (0.0–0.2)</td>
</tr>
<tr>
<td>Bone Alkaline Phosphatase (U/l)</td>
<td>ME ± SD</td>
<td>19.7 ± 15.0a</td>
<td>37.6 ± 20.0b</td>
<td>36.1 ± 10.3b,c</td>
<td>25.4 ± 18.0</td>
</tr>
<tr>
<td>Osteocalcin (ng/ml)</td>
<td>MED (MIN-MAX)</td>
<td>6.8a (4.4–9.0)</td>
<td>14.1b (8.8–18.6)</td>
<td>15.5c (10.3–23.1)</td>
<td>16.5b,c (6.8–23.0)</td>
</tr>
</tbody>
</table>

PLWHA: People living with HIV/AIDS; G1: PLWA antirretroviral therapy (ART)-naïve; G2: PLWHA under ART for less than 2 years; G3: PLWHA under ART for 2 to 10 years; G4: PLWHA on ART for more than 10 years. ME: Mean; SD: Standard Deviation; MED: Median; MIN-MAX: Minimum and Maximum; GFR: Glomerular Filtration Rate; CKD-EPI: Chronic Kidney Disease Epidemiology Collaboration; PTH: Parathyromone; BMD: Bone Densitometry; CTX: C-terminal Telopeptid; NS: Not Significant. Statistical test used: Multiple Comparison (ANOVA) followed by Tukey–Kramer post hoc tests and Kruskal–Wallis. Distinct letters (a, b and c) represent statistical differences.
**Bone diseases**

Several studies have reported greater bone loss with high rates of osteopenia and osteoporosis in PLWHA (Bonjoch et al., 2010; Brown and Qaqish, 2006; Ofotokun et al., 2016), which may be three times more common in this population, compared to uninfected individuals (Gallant et al., 2004; Harris and Brown, 2012; Kwak et al., 2019). In general, in this study, the prevalence of osteopenia/osteoporosis was high (53.2%), a very similar result to that found by another Brazilian study, conducted by Pinto-Neto et al. (2011), whose prevalence was 54.7%. However, as shown in Fig. 3, a curious fact observed here was the high frequency of these changes, found not only in G4 (62.5%), in which it was expected due to the influence of ART, but also in G1 (63.7%), a group of individuals still without treatment, while the other groups showed intermediate prevalence (G2, 36.4% and G3, 53.0%). In a way, this high occurrence in G1 can be explained by the fact that HIV itself induces an inflammatory state that can lead to bone loss through the promotion of osteoclastogenesis and bone resorption induced by inflammatory cytokines (Gallant et al., 2004).

In the pre-ART era, advanced HIV infection was associated with low levels of bone formation markers and high levels of bone resorption. However, with the start of therapy, increases in both markers were observed, indicating an increase in bone turnover (Brown et al., 2009; Kwak et al., 2019).

In this study, BMD and CTX levels were not different between groups. To further the analysis of bone changes, we investigated levels of phosphorus and calcium, which were also similar between groups, with levels of PTH, vitamin D, OC, total alkaline phosphatase (tALP) and BAP showing significant differences between groups. Thus, despite the high frequency of osteopenia in G1 and G4, greater bone involvement was evident in the groups undergoing ART, as the G1 individuals had lower levels of PTH, tALP, BAP and OC in relation to the other groups, in addition to higher levels of vitamin D. These data are shown in Table 2.

It is worth mentioning that in Pearson’s analysis, positive correlations were found between osteocalcin and the duration of therapy (p = 0.05), especially with the use of PI (p = 0.004). The interference of this class of antiretroviral in osteoblastic differentiation was also demonstrated in a study by Hirakawa et al. (2017), whose change to integrase inhibitors normalized this profile. Similarly, Bonnet et al. (2013) also reported early BMD loss in patients who started a PI regimen, which was correlated with gain in fat mass by such individuals. However, active bone modeling was evident with all antiretroviral regimens, associated with low levels of vitamin D and hyperparathyroidism.

Contrary to our results, a decrease in BMD was reported in a longitudinal study conducted by Madeddu et al. (2015b), performed on PLWHA treated for a long period. However, these authors also associated more changes in those with PI, compared to those using NNRTI, emphasizing that the mechanism by which ART acts on the bone structure is still unclear, but that some hypotheses can be made about its direct action on bone remodeling and/or indirect action on the vitamin-D metabolism, thus aggravating bone loss due to HIV infection itself. Other studies have also shown that bone changes are more frequent in individuals under ART regimens containing tenofovir than in those in regimens without this drug Bolland et al., 2015; Stellbrink et al., 2010; Vlot et al., 2018). However, in this study, the specific drugs used by patients were not analyzed, but only the ART schemes/regimens.

In general, it was observed that the levels of PTH, a hormone responsible for regulating the levels of phosphorus and calcium in the body, were within normal limits (data not shown) in the studied population. Regarding vitamin D, most individuals had desirable levels, but more than 12% of patients on ART had insufficient levels of this marker, suggesting a likely influence of therapy on such reduction, which occurred mainly in patients using efavirenz. These results are in agreement with those found by Dao et al. (2011) and Brown and McComsey (2010), who associated vitamin-D deficiency with the use of this drug. Wohl et al. (2014) also noted that individuals on ART using efavirenz or rilpivirine had a significant decrease in vitamin-D levels 48 weeks after starting treatment.

There were no differences between groups regarding the risk of fractures in 10 years, as analyzed by the FRAX tool. It should be noted that FRAX was performed only on patients aged 40 years or older, which left us with a small number of individuals for analysis. However, our results are similar to those found in a systematic review and meta-analysis, in which it was suggested that both HIV infection and ART use are associated with a slight increase in the risk for fractures. However, the use of the FRAX tool for the HIV-infected population is not yet validated and is still under study (Shiau et al., 2013; Yin and Falutz, 2016).

In summary, 64% of patients studied here were dyslipidemias, 12.1% presented moderate and high-Framingham Risk Score and 20% showed stage-2 and stage-3 renal alterations. All these changes were more expressive in those that had been using ART for a longer period of time. High prevalences of osteopenia and osteoporosis (53.2%) were found, especially in the naive group and in those under longer ART use; however, the first group had lower levels of tALP, BAP and osteocalcin, in addition to higher concentrations of vitamin D than the others. ART-naive individuals also showed the lowest CPK levels.

It is worth mentioning this study had some limitations, such as its cross-sectional design, a small sample and a small sampled number of patients with FRAX results, since those under 40 years old were excluded.

**Conclusions**

Our study showed the possible contributory role of antiretrovirals in metabolic, cardiac, renal and bone changes in patients with ART adherence and undetectable VL, because we found a high prevalence of changes in the markers analyzed here, especially in people who have been using ART for a long time. These data reinforce the importance of an early diagnosis of such dysfunctions in PLWHA, as well as the approach to the management of these comorbidities, considering their associated factors.

**Conflict of interests**

The authors declare that they have no conflicts of interest.

**Ethical approval**

This study was approved by the Research Ethics Committees of the Botucatu Medical School (FMB/UNESP), and the whole research process followed the principles of the Helsinki Declaration.

**Informed consent**

Informed consent was obtained from all individual participants included in the study.
Role of the funding source

São Paulo Research Foundation (FAPESP, Proc. 2016/15440-4) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Acknowledgements

We thank the patients for their participation and all the employees at the Specialized Outpatient Service for Infectious Diseases “Domingos Alves Meira” for their endeavors. We would also like to thank EAP/UNESP and Dr. José Eduardo Corrente, in particular, for his assistance with statistical analysis, and finally acknowledge the financial support provided by São Paulo Research Foundation (FAPESP, Proc. 2016/15440-4) and Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

References


